The Safety and Efficacy of Bipolar Plasma-Kinetic Transurethral Resection of The Prostate in Patients Taking Low-Dose Aspirin
Urology Journal,
Vol. 20 No. 06 (2023),
26 December 2023
,
Page 419-423
https://doi.org/10.22037/uj.v20i.7508
Abstract
Purpose: To explore the safety and efficacy of bipolar plasma-kinetic transurethral resection of the prostate in patients taking low-dose aspirin.
Materials and Methods: Benign prostatic hyperplasia (BPH) patients who underwent surgical treatment from November 2018 to May 2020 were retrospectively analyzed, and divided into two groups according to whether taking 100mg aspirin daily aspirin or not. The perioperative indexes, complications and sequelae also were used to evaluate safety. The efficacy was evaluated by the functional outcomes in 3,6,12 months.
Results: There were no statistical differences in the baseline characteristics or perioperative indicators and complications and sequelae, except for a longer operative time(90.49 ± 14.34 vs 84.95 ± 15.49; 95%CI: 0.26-10.83; P = .040) and a shorter hospital stay time(HST) (8.52 ± 1.55 vs 9.09 ± 1 .50; 95% CI: 0.21-1.11; P = .042) in the non-aspirin group. During the 12-months follow-up period, the functional outcomes of the two groups were significantly improved except International Index of Erectile Function (IIEF-5).
Conclusion: Based on our research results, PKRP a safe and effective method for patients with BPH who taking 100mg aspirin daily.
- Benign prostatic hyperplasia
- Bipolar plasma-kinetic transurethral resection of the prostate
- Aspirin
How to Cite
References
Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia - what do we know? BJU Int.2021;127:389-399.
Gupta K, Yezdani M, Sotelo T, Aragon-Ching JB. A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs.2015;24: 1059-73.
Noble SM, Ahern AM, Worthington J, et al. The cost-effectiveness of transurethral resection of the prostate vs thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic obstruction. BJU Int.2020;126: 595-603.
Falsaperla M, Cindolo L, Saita A, et al. Transurethral resection of prostate: technical progress by bipolar Gyrus plasma-kinetic tissue management system.Minerva Urol Nefrol.2007; 59: 125-9.
Li S, Kwong JS, Zeng XT, et al. Plasmakinetic resection technology for the treatment of benign prostatic hyperplasia: evidence from a systematic review and meta-analysis. Sci Rep.2015;5: 12002.
Rhee TG, Kumar M, Ross JS, Coll PP. Age-Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011-2018. J Am Geriatr Soc 2021;69: 1272-1282.
Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol.2015; 22:1-6.
Sajan A, Mehta T, Desai P, Isaacson A, Bagla S. Minimally invasive treatments for benign prostatic hyperplasia: a Cochrane network meta-analysis. BJU Int.2022; 33: 359-367.
Dean E, Bruce G, Steven L, Naeem B, Kevin CZ, Bilal C. New Technologies for Treatment of Benign Prostatic Hyperplasia. Urol Clin North Am.2022;49: 11-22.
Gravas S, Cornu JN, Gacci M, et al. EAU Guidelines: Management of Nonneurogenic Male LUTS. European Association of Urology. 2019.
Dincel C, Samli MM, Guler C, Demirbas M, Karalar M. Plasma kinetic vaporization of the prostate: clinical evaluation of a new technique. J Endourol.2004;18: 293-8.
Xiao KW, Zhou L, He Q, et al. Transurethral endoscopic enucleation of the prostate using a diode laser versus bipolar plasmakinetic for benign prostatic obstruction: a meta-analysis. Lasers Med Sci.2020;35: 1159-1169.
Ricciotti E, FitzGerald GA. Aspirin in the Prevention of Cardiovascular Disease and Cancer. Annu Rev Med.2021;72: 473-495.
Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med.1983；309: 396-403.
Collet JP, Himbet F, Steg PG.Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardio.2000;l76: 257-8.
Gerstein NS, Schulman PM, Gerstein WH, Petersen TR, Tawil I. Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome. Ann Surg.2012;255: 811-9.
Culkin DJ, Exaire EJ, Green D, et al.Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol. 2014;192(4): 1026-34.
Erturhan S, Erbagci A, Seckiner I, Yagci F, Ustun A. Plasmakinetic resection of the prostate versus standard transurethral resection of the prostate: a prospective randomized trial with 1-year follow-up. Prostate Cancer Prostatic Dis.2007;10: 97-100.
Liu Z, Li YW, Wu WR, Lu Q.Long-term Clinical Efficacy and Safety Profile of Transurethral Resection of Prostate Versus Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia. Urology.2017;103: 198-203.
Otaola-Arca H, Álvarez-Ardura M, Molina-Escudero R, Fernández MI, Páez-Borda Á. A prospective randomized study comparing bipolar plasmakinetic transurethral resection of the prostate and monopolar transurethral resection of the prostate for the treatment of Benign Prostatic Hyperplasia: efficacy, sexual function, Quality of Life, and complications. Int Braz J Urol.2021;47: 131-144.
Cheng X, Qin C, Xu P, et al.Comparison of bipolar plasmakinetic resection of prostate versus photoselective vaporization of prostate by a three year retrospective observational study. Sci Rep.2021;11: 10142.
El-Shaer W, Abou-Taleb A, Kandeel W. Transurethral bipolar plasmakinetic vapo-enucleation of the prostate: Is it safe for patients on chronic oral anticoagulants and/or platelet aggregation inhibitors? Arab J Urol. 2017; 15:347-354.
- Abstract Viewed: 442 times
- 7508/pdf Downloaded: 240 times